Mediwound Ltd
MDWD17.790USD
+0.570+3.31%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
228.09M시가총액
손실P/E TTM
자세한 내용은 Mediwound Ltd 회사
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Mediwound Ltd 정보
종목 코드 MDWD
회사 이름Mediwound Ltd
상장일Mar 20, 2014
CEOGonen (Ofer)
직원 수111
유형Ordinary Share
회계 연도 종료Mar 20
주소42 Hayarkon Street
도시YAVNE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Israel
우편 번호8122745
전화972779714100
웹사이트https://www.mediwound.com/
종목 코드 MDWD
상장일Mar 20, 2014
CEOGonen (Ofer)
Mediwound Ltd의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Ofer Gonen
Mr. Ofer Gonen
Chief Executive Officer, Director
Chief Executive Officer, Director
182.10K
+83371.00%
Dr. Vickie R. Driver, M.D.
Dr. Vickie R. Driver, M.D.
Independent Director
Independent Director
--
--
Mr. Stephen T. Wills, CPA
Mr. Stephen T. Wills, CPA
Independent Director
Independent Director
--
--
Dr. Ety Klinger, Ph.D.
Dr. Ety Klinger, Ph.D.
Chief Research and Development Officer
Chief Research and Development Officer
--
--
Mr. Yaron Meyer
Mr. Yaron Meyer
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
--
--
Mr. David Fox
Mr. David Fox
Independent Director
Independent Director
--
--
Mr. Jeremy Feffer
Mr. Jeremy Feffer
Managing Director
Managing Director
--
--
Mr. Shmuel (Milky) Rubinstein
Mr. Shmuel (Milky) Rubinstein
Independent Director
Independent Director
--
--
Dr. Shmulik Hess
Dr. Shmulik Hess
Chief Operating Officer, Chief Commercial Officer
Chief Operating Officer, Chief Commercial Officer
--
--
Ms. Hani Luxenburg
Ms. Hani Luxenburg
Chief Financial Officer
Chief Financial Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Ofer Gonen
Mr. Ofer Gonen
Chief Executive Officer, Director
Chief Executive Officer, Director
182.10K
+83371.00%
Dr. Vickie R. Driver, M.D.
Dr. Vickie R. Driver, M.D.
Independent Director
Independent Director
--
--
Mr. Stephen T. Wills, CPA
Mr. Stephen T. Wills, CPA
Independent Director
Independent Director
--
--
Dr. Ety Klinger, Ph.D.
Dr. Ety Klinger, Ph.D.
Chief Research and Development Officer
Chief Research and Development Officer
--
--
Mr. Yaron Meyer
Mr. Yaron Meyer
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
--
--
Mr. David Fox
Mr. David Fox
Independent Director
Independent Director
--
--
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2024
FY2023
FY2022
FY2021
FY2020
기업이 아직 관련 데이터를 공개하지 않았습니다.
지역별USD
이름
수익
비율
USA
15.46M
76.47%
EU and other international markets
4.76M
23.53%
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Sat, Jan 31
마지막 업데이트: Sat, Jan 31
주주
주주 유형
주주
주주
비율
Clal Biotechnology Industries Ltd
11.54%
Investor AB
6.79%
Yelin Lapidot Provident Funds Management Ltd
5.95%
Rosalind Advisors, Inc.
5.84%
HOLD Alapkezelo Zrt
5.48%
기타
64.40%
주주
주주
비율
Clal Biotechnology Industries Ltd
11.54%
Investor AB
6.79%
Yelin Lapidot Provident Funds Management Ltd
5.95%
Rosalind Advisors, Inc.
5.84%
HOLD Alapkezelo Zrt
5.48%
기타
64.40%
주주 유형
주주
비율
Investment Advisor
22.88%
Holding Company
11.54%
Hedge Fund
10.80%
Investment Advisor/Hedge Fund
8.43%
Private Equity
6.79%
Venture Capital
2.95%
Corporation
2.17%
Individual Investor
1.42%
Research Firm
0.83%
기타
32.19%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
148
6.98M
54.40%
+1.60M
2025Q3
135
5.72M
44.57%
+391.20K
2025Q2
127
6.70M
61.97%
-1.10M
2025Q1
129
6.76M
62.72%
-1.01M
2024Q4
118
7.26M
67.33%
+161.02K
2024Q3
115
7.34M
70.49%
+440.76K
2024Q2
91
5.75M
66.40%
+288.97K
2024Q1
69
5.35M
61.63%
-376.56K
2023Q4
61
5.55M
64.63%
+32.10K
2023Q3
62
5.26M
71.22%
+1.01M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Clal Biotechnology Industries Ltd
1.48M
11.55%
--
--
Sep 30, 2025
Investor AB
872.09K
6.8%
--
--
Sep 30, 2025
Yelin Lapidot Provident Funds Management Ltd
809.95K
6.32%
-6.79K
-0.83%
Sep 30, 2025
Rosalind Advisors, Inc.
749.05K
5.84%
+341.99K
+84.02%
Sep 30, 2025
HOLD Alapkezelo Zrt
703.43K
5.49%
+703.43K
--
Sep 22, 2025
T. Rowe Price Associates, Inc.
599.38K
4.67%
+230.30K
+62.40%
Sep 30, 2025
Israel Biotech Fund
378.62K
2.95%
-172.63K
-31.32%
Mar 15, 2025
BlackRock Institutional Trust Company, N.A.
363.39K
2.83%
-24.88K
-6.41%
Sep 30, 2025
Meitav Investment House Ltd
291.62K
2.27%
+260.12K
+825.71%
Sep 30, 2025
Deep Insight Limited Partnership
278.18K
2.17%
-273.07K
-49.54%
Mar 15, 2025
더 보기
관련 ETF
마지막 업데이트: Tue, Dec 2
마지막 업데이트: Tue, Dec 2
이름
비율
ARK Israel Innovative Technology ETF
1.64%
Invesco NASDAQ Future Gen 200 ETF
0.59%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
ARK Israel Innovative Technology ETF
비율1.64%
Invesco NASDAQ Future Gen 200 ETF
비율0.59%
iShares Micro-Cap ETF
비율0.03%
iShares Russell 2000 Growth ETF
비율0.01%
Global X Russell 2000 ETF
비율0.01%
ProShares Hedge Replication ETF
비율0.01%
iShares Russell 2000 ETF
비율0%
Proshares Ultra Russell 2000
비율0%
ProShares UltraPro Russell2000
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
날짜
배당락일
유형
비율
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
Dec 19, 2022
Merger
7→1
